Stem-cell-derived islets (zimislecel / VX-880)

Type 1 diabetes destroys the insulin-producing islet cells of the pancreas, leaving people dependent on injected insulin for life. Zimislecel (formerly VX-880) aims to replace those lost cells rather than just dose around their absence. Vertex grows fully differentiated, insulin-producing islet cells from pluripotent stem cells — in principle an unlimited, standardized supply — and infuses them as a single dose into the hepatic portal vein (the liver's main blood vessel), where they engraft and secrete insulin in response to blood glucose.¹ Because the cells come from a donor stem-cell line rather than the recipient, this is allogeneic: patients also take chronic immune-suppressing drugs to stop rejection.¹ This makes zimislecel the leading "cell-replacement cure" candidate — an off-the-shelf source of islets, in contrast to therapies limited by scarce deceased-donor pancreases.²

The clinical evidence

The pivotal data come from the FORWARD study (VX-880-101, ClinicalTrials.gov NCT04786262), a Phase 1/2/3 trial whose interim Phase 1/2 results were published in the New England Journal of Medicine in June 2025.¹ In Part A, participants received a half dose; in Parts B and C they received a full single dose of 0.8 billion cells, all with glucocorticoid-free immunosuppression.¹ Among the 14 participants followed at least 12 months, every one had undetectable C-peptide (no own insulin production) at baseline — and after infusion, all showed engraftment and restored insulin production.¹

The results in the 12 fully dosed recipients are striking: all 12 were free of severe hypoglycemic events from day 90 onward, all reached HbA1c below 7%, and all spent more than 70% of the day in the target glucose range of 70-180 mg/dL (3.9-10 mmol/L).¹ Ten of the 12 (83%) were completely off injected insulin at one year,¹ with a mean reduction in daily insulin dose of about 92% across the group.³ Glucose-responsive C-peptide was durable through the full 12 months of follow-up.³ These are the strongest human results yet for stem-cell-derived islets — but the data are interim, short-term and from a small group, so longer-term durability remains to be proven.¹

Eligibility and safety

FORWARD enrolls adults aged 18-65 with type 1 diabetes for more than five years who have impaired awareness of hypoglycemia and a history of severe hypoglycemic events.⁴ The most common serious adverse event was neutropenia (low white-cell counts), in 3 participants.¹ Two deaths occurred — one from cryptococcal meningitis and one from progression of pre-existing dementia — both judged unrelated to zimislecel.¹ The major standing caveat is the need for lifelong immunosuppression, which carries its own risks of infection and toxicity and is why the therapy is restricted to severe cases.¹

Phase and proximity to availability

Zimislecel is now in the pivotal Phase 3 portion of FORWARD, dosing roughly 50 participants.² It holds Regenerative Medicine Advanced Therapy (RMAT) and Fast Track designations from the U.S. FDA, PRIME designation from the European Medicines Agency, and an Innovation Passport under the UK MHRA's Innovative Licensing and Access Pathway.²

Vertex had guided to marketing applications in 2026, but that timing is now in doubt. Dosing in FORWARD was paused pending an internal manufacturing analysis and resumed only recently: in its first-quarter 2026 results Vertex said it had completed the analysis, restarted dosing, and "expects to provide updated timelines for study completion later this year" — it did not repeat the 2026 filing guidance, and its own forward-looking-statements list for zimislecel now covers only those updated study-completion timelines, with no regulatory submission mentioned at all.⁵ On the accompanying earnings call, management said it would update investors "in the coming months on the revised timelines, study completion, and regulatory filings."⁶ The trial registry, last updated in June 2026, still lists FORWARD as recruiting, with primary completion in June 2027 and study completion in 2030.⁴ No filing had been announced as of July 2026. This is a timeline in flux, not a safety or efficacy problem — the Phase 1/2 results above are unchanged.

What's coming

Whenever Vertex does file, zimislecel could become the first approved stem-cell-derived islet therapy — but as an immunosuppression-dependent product, its initial use would stay limited to people with the most dangerous hypoglycemia.¹ The near-term milestone to watch is narrower than an approval: Vertex's Q1 2026 release promises updated study-completion timelines later this year, and on the accompanying earnings call management extended that to the regulatory filings as well.⁵⁶

The real prize is removing the immunosuppression requirement — and Vertex has already lost one attempt at it. Its device-encapsulated version, VX-264, was discontinued in March 2025 after the implanted cells proved safe but failed to raise C-peptide to levels that delivered benefit; Vertex booked a $379 million intangible-asset impairment on the programme (see our VX-264 record).⁷⁸ Killing VX-264 did not, however, take encapsulation off Vertex's list. The same March 2025 update named three research routes the company is still pursuing toward dropping systemic immunosuppression: alternative immunosuppressive regimens, gene-edited hypoimmune stem-cell-derived islets, and novel devices to encapsulate islet cells.⁷ All three are research-stage rather than products in development, so a cell-replacement therapy for the broad T1D population is not close.⁷

References

1. Reichman TW, Markmann JF, Odorico J, et al. Stem Cell-Derived, Fully Differentiated Islets for Type 1 Diabetes. N Engl J Med (2025);393(9):858-868. According to PubMed. https://doi.org/10.1056/NEJMoa2506549 ↩ ↩² ↩³ ↩⁴ ↩⁵ ↩⁶ ↩⁷ ↩⁸ ↩⁹ ↩¹⁰ ↩¹¹ ↩¹²

2. Vertex Pharmaceuticals. Vertex Presents Positive Data for Zimislecel in Type 1 Diabetes at the American Diabetes Association 85th Scientific Sessions. Vertex Newsroom (2025). https://news.vrtx.com/news-releases/news-release-details/vertex-presents-positive-data-zimislecel-type-1-diabetes ↩ ↩² ↩³

3. Monostra M. Zimislecel, a novel cell therapy, appears to restore islet function in type 1 diabetes. Healio (2025). https://www.healio.com/news/endocrinology/20250621/zimislecel-a-novel-cell-therapy-appears-to-restore-islet-function-in-type-1-diabetes ↩ ↩²

4. A Study to Evaluate the Safety, Tolerability, and Efficacy of VX-880 in Participants With Type 1 Diabetes (FORWARD). ClinicalTrials.gov, NCT04786262 (record last updated 2026-06-26; accessed 2026-07-14). https://clinicaltrials.gov/study/NCT04786262 ↩ ↩²

5. Vertex Pharmaceuticals. Vertex Reports First Quarter 2026 Financial Results. Vertex Newsroom (2026-05-04). https://news.vrtx.com/news-releases/news-release-details/vertex-reports-first-quarter-2026-financial-results ↩ ↩²

6. Vertex Pharmaceuticals (VRTX) Q1 2026 earnings call transcript. The Motley Fool (2026-05-04). https://www.fool.com/earnings/call-transcripts/2026/05/04/vertex-vrtx-q1-2026-earnings-call-transcript/ ↩ ↩²

7. Vertex Pharmaceuticals. Vertex Announces Program Updates for Type 1 Diabetes Portfolio. Vertex Newsroom (2025-03-28). https://news.vrtx.com/news-releases/news-release-details/vertex-announces-program-updates-type-1-diabetes-portfolio ↩ ↩² ↩³

8. Vertex Pharmaceuticals. Vertex Reports First Quarter 2025 Financial Results. Vertex Newsroom (2025-05-05). https://investors.vrtx.com/news-releases/news-release-details/vertex-reports-first-quarter-2025-financial-results ↩